A detailed history of Raymond James & Associates transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 82,006 shares of REGN stock, worth $57.6 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
82,006
Previous 74,228 10.48%
Holding current value
$57.6 Million
Previous $78 Million 10.5%
% of portfolio
0.05%
Previous 0.05%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$1024.09 - $1201.76 $7.97 Million - $9.35 Million
7,778 Added 10.48%
82,006 $86.2 Million
Q2 2024

Jul 19, 2024

BUY
$883.2 - $1071.19 $2.55 Million - $3.09 Million
2,887 Added 4.05%
74,228 $78 Million
Q1 2024

Apr 22, 2024

BUY
$902.69 - $993.35 $3.92 Million - $4.31 Million
4,342 Added 6.48%
71,341 $68.7 Million
Q4 2023

Jan 16, 2024

BUY
$775.18 - $881.7 $4.26 Million - $4.85 Million
5,499 Added 8.94%
66,999 $58.8 Million
Q3 2023

Oct 24, 2023

SELL
$692.45 - $844.37 $8,309 - $10,132
-12 Reduced 0.02%
61,500 $50.6 Million
Q2 2023

Jul 25, 2023

SELL
$700.03 - $830.35 $394,816 - $468,317
-564 Reduced 0.91%
61,512 $44.2 Million
Q1 2023

Apr 14, 2023

BUY
$680.49 - $826.97 $550,516 - $669,018
809 Added 1.32%
62,076 $51 Million
Q4 2022

Feb 08, 2023

SELL
$705.89 - $766.39 $3.75 Million - $4.08 Million
-5,318 Reduced 7.99%
61,267 $44.2 Million
Q3 2022

Oct 25, 2022

SELL
$573.97 - $724.32 $642,846 - $811,238
-1,120 Reduced 1.65%
66,585 $45.9 Million
Q2 2022

Aug 12, 2022

SELL
$548.35 - $738.84 $12 Million - $16.2 Million
-21,860 Reduced 24.41%
67,705 $40 Million
Q1 2022

May 11, 2022

SELL
$595.12 - $698.43 $1.46 Million - $1.71 Million
-2,454 Reduced 2.67%
89,565 $62.6 Million
Q4 2021

Feb 08, 2022

SELL
$543.48 - $670.97 $2.31 Million - $2.86 Million
-4,256 Reduced 4.42%
92,019 $58.1 Million
Q3 2021

Nov 02, 2021

SELL
$574.03 - $680.96 $2.82 Million - $3.34 Million
-4,908 Reduced 4.85%
96,275 $58.3 Million
Q2 2021

Aug 11, 2021

BUY
$472.8 - $558.54 $4.72 Million - $5.58 Million
9,986 Added 10.95%
101,183 $56.5 Million
Q1 2021

May 14, 2021

SELL
$446.73 - $548.2 $1.54 Million - $1.89 Million
-3,453 Reduced 3.65%
91,197 $43.1 Million
Q4 2020

Feb 12, 2021

BUY
$478.3 - $607.98 $293,676 - $373,299
614 Added 0.65%
94,650 $45.7 Million
Q3 2020

Nov 04, 2020

SELL
$544.75 - $658.21 $1.44 Million - $1.74 Million
-2,649 Reduced 2.74%
94,036 $52.6 Million
Q2 2020

Jul 28, 2020

BUY
$493.32 - $643.92 $6.28 Million - $8.2 Million
12,733 Added 15.17%
96,685 $60.3 Million
Q1 2020

Apr 21, 2020

BUY
$336.18 - $494.43 $4.15 Million - $6.1 Million
12,340 Added 17.23%
83,952 $41 Million
Q4 2019

Feb 12, 2020

BUY
$274.13 - $376.51 $828,969 - $1.14 Million
3,024 Added 4.41%
71,612 $26.9 Million
Q3 2019

Nov 07, 2019

BUY
$273.46 - $318.39 $3.2 Million - $3.73 Million
11,706 Added 20.58%
68,588 $19 Million
Q2 2019

Aug 06, 2019

BUY
$299.6 - $414.82 $913,480 - $1.26 Million
3,049 Added 5.66%
56,882 $17.8 Million
Q1 2019

May 06, 2019

SELL
$372.08 - $439.57 $6.68 Million - $7.9 Million
-17,962 Reduced 25.02%
53,833 $22.1 Million
Q4 2018

Feb 11, 2019

SELL
$335.82 - $403.04 $3.45 Million - $4.14 Million
-10,267 Reduced 12.51%
71,795 $26.8 Million
Q3 2018

Nov 14, 2018

BUY
$351.14 - $408.51 $51,266 - $59,642
146 Added 0.18%
82,062 $33.2 Million
Q2 2018

Aug 14, 2018

BUY
$284.6 - $344.99 $8.5 Million - $10.3 Million
29,864 Added 57.37%
81,916 $28.3 Million
Q1 2018

May 14, 2018

BUY
$315.82 - $393.78 $3.35 Million - $4.18 Million
10,615 Added 25.62%
52,052 $17.9 Million
Q4 2017

Feb 14, 2018

SELL
$358.63 - $469.95 $1.09 Million - $1.43 Million
-3,053 Reduced 6.86%
41,437 $15.6 Million
Q3 2017

Nov 13, 2017

BUY
$431.38 - $504.0 $888,211 - $1.04 Million
2,059 Added 4.85%
44,490 $19.9 Million
Q2 2017

Aug 14, 2017

BUY
N/A
42,431
42,431 $20.8 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.